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Abstract
Objective: To evaluate the capacity of the criteria described in Complementary Directive SAS/MS 12, issued on 
November 12, 2002, to identify patients with severe asthma, describing and comparing clinical, functional and 
treatment data of such patients. Methods: This was a nested case-control study using a structured database 
for adult asthma outpatients. We defined cases as asthma patients who met the inclusion criteria described in 
the directive, defining controls as those who did not. We collected and compared data related to the following: 
demographic characteristics; history of asthma; medications in use; comorbidities; history of tobacco use; number 
of exacerbations within the last 12 months, asthma-related hospitalizations and intensive care unit admissions 
within the last 12 months; spirometry; and sputum cytology. Results: The case and control groups consisted 
of 29 and 31 patients, respectively. The number of asthma exacerbations and emergency room visits within the 
last 12 months, as well as the number of patients that received at least one pulse of oral corticosteroids, was 
significantly higher in the case group than in the control group. In addition, prebronchodilator FVC was lower 
among the cases than among the controls. Furthermore, cytology revealed that eosinophil counts were significantly 
higher in the induced sputum of cases than in that of controls. Conclusions: The criteria described in the directive 
are suited to stratifying patients with severe asthma.
Keywords: Asthma; Budesonide; Combined modality therapy.
Resumo
Objetivo: Avaliar a capacidade dos critérios descritos na Portaria Complementar SAS/MS n°12, de 12 de novembro 
de 2002, em identificar pacientes asmáticos graves, bem como descrever e comparar dados clínicos, funcionais 
e de tratamento destes pacientes. Métodos: Estudo caso-controle aninhado em um banco de dados estruturado 
de atendimento ambulatorial de asmáticos. Foram considerados casos os pacientes asmáticos que preencheram 
os critérios de inclusão determinados na portaria e considerados controles os que não preencheram os mesmos 
critérios. Foram coletados e comparados dados demográficos; história pregressa da asma; medicamentos em uso; 
presença de comorbidades; história de tabagismo; presença, no último ano, de exacerbações, de hospitalizações 
e de admissões em unidades de terapia intensiva devido à asma; e resultados de espirometria e de citologia de 
escarro. Resultados: Foram incluídos 29 e 31 pacientes, respectivamente, nos grupos caso e controle. O grupo 
caso apresentou maior número de exacerbações e maior número de visitas ao pronto-socorro no último ano, maior 
porcentagem de pacientes que receberam pelo menos um pulso de corticosteroide oral, assim como menores 
valores de CVF pré-broncodilatador em relação ao grupo controle. O grupo caso também apresentou um aumento 
significante de eosinófilos na citologia do escarro induzido. Conclusões: Os critérios de inclusão descritos na 
portaria são adequados para estratificar pacientes com asma grave. 
Descritores: Asma; Budesonida; Terapia combinada.
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Brazil is limited access to medication, especially 
for low-income populations.(4)
On 23 July, 2002, the Brazilian Federal 
Government approved Directive 1318/GM, 
published in the Official Federal Government 
Gazette, which ordered the distribution of medi-
cation at no charge to patients diagnosed with 
severe asthma.(4,10) The criteria for the inclu-
sion and exclusion of patients in this program 
are set forth in the Complementary Directive of 
the Secretaria de Atenção à Saúde/Ministério 
da Saúde (SAS/MS, Health Care Department/
National Ministry of Health) no. 12, issued on 
12 November, 2002.(4,10)
The present study was aimed at evaluating 
the capacity of the aforementioned directive 
criteria in identifying this population of asthma 
patients, as well as at describing and comparing 
clinical, functional and treatment data for 
the monitoring of a sample of adult asthma 
patients.
Methods
This was an observational nested case-con-
trol study, using a database structured for the 
monitoring of adult asthma patients.
In the period between January of 2005 and 
February of 2007, regularly monitored and 
treated patients were consecutively interviewed, 
as recommended by the ATS,(5) in the Hospital 
São Paulo Asthma Research Outpatient Clinic, 
Universidade Federal de São Paulo (Unifesp, 
Federal University of São Paulo), in the city of 
São Paulo, Brazil.
This study was approved by the Unifesp Ethics 
in Research Committee and was conducted in 
accordance with the ethical principals estab-
lished in the Declaration of Helsinki.
The inclusion criteria were as follows: being 
aged between 16 and 80 years, being diagnosed 
with asthma according to the 2004 Global 
Initiative for Asthma (GINA) criteria(11); agreeing 
to participate in the study; undergoing spirom-
etry with bronchodilator test during the initial 
evaluation (at inclusion); and having had at 
least three documented evaluations in the year 
preceding the inclusion date.
Cases were defined as patients who met the 
inclusion criteria to receive the benefit granted 
by the directive with the completion of the 
“Exceptional Medication Request” (EMR) form. 
Controls were defined as asthma patients who 
Introduction
Asthma is a chronic inflammatory disease 
and, according to the multicenter International 
Study of Asthma and Allergies in Childhood, the 
mean worldwide prevalence is 11.6% among 
schoolchildren aged 6-7 years and 13.7% among 
adolescents aged 13-14 years.(1) In Brazil, asthma 
prevalence rates remain elevated, approximately 
20% for those same two age brackets.(2-4)
Most cases present with mild or intermittent 
clinical expression, although 25-30% of patients 
have moderate asthma and 5-10% have severe 
asthma.(4) Although patients with severe asthma 
are the minority, they account for a significant 
portion of the health care resources allocated.(3)
One of the first definitions of “severe asthma” 
was given by the American Thoracic Society 
(ATS),(5) which recommended that patients who 
presented at least one major criterion and two 
minor criteria be considered patients with severe 
asthma. The major criteria are using high doses 
of inhaled corticosteroids or using oral corticos-
teroids on a continuous basis (or during at least 
50% of the preceding year). The minor criteria 
include aspects of pulmonary function, exacer-
bations, stability of the disease and the use of 
one or more additional medications (long-acting 
bronchodilator, theophylline or leukotriene 
antagonists) in order to obtain control.(5)
Since the recent advent of effective manage-
ment for the control of the disease, the term 
“controlled asthma” has been used. The concept 
of controlled disease is different from the 
concept of severity, although some variables be 
included in the definition of both.(6) Patients with 
uncontrolled severe asthma are likely to experi-
ence frequent exacerbations and to contribute 
disproportionately to the total costs of the 
treatment.(7) In a study evaluating the economic 
cost of asthma, carried out at our facility, it was 
observed that patients with controlled asthma 
accounted for lower health care expenditures 
than did those with uncontrolled asthma, due 
to a decrease in the number of emergency room 
visits as well as in the number of hospitaliza-
tions.(3) It is known that 80% of the users of 
emergency rooms who are frequently hospi-
talized due to asthma are those who did not 
comply with treatment and maintenance recom-
mendations.(5,8,9) In addition, one of the obstacles 
to asthma maintenance treatment adherence in 
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talizations, as well as the lifetime/previous-year 
incidence of admission to the intensive care unit 
(ICU).
We obtained the following information as for 
the use of asthma medications: dose of inhaled 
corticosteroid for maintenance treatment in the 
preceding three months, the use of oral corticos-
teroid in the preceding year; use of short-acting 
and long-acting bronchodilator; and use of 
methylxanthines, antileukotrienes, anticholiner-
gics or chromones.
The evaluation of asthma control, at the 
time of inclusion, was based on the standardized 
algorithm on the patient chart, in compliance 
with the 2006 GINA criteria.(2) Therefore, as a 
conclusion of the evaluation, the patient was 
classified according to the level of control of the 
disease: controlled, partially controlled, uncon-
trolled or exacerbated.(2)
We also evaluated the systemic presence of 
the following comorbidities: rhinitis, gastro-
esophageal reflux, systemic arterial hypertension 
and obesity.
In the case of former smokers, we collected 
information on the history of smoking: age at 
smoking onset; tobacco intake, expressed as 
pack-years; and the date of smoking cessation. 
Nonsmokers were defined as individuals with 
tobacco exposure of less than one pack-year. 
Former smokers were defined as individuals who 
had quit smoking more than five years prior.
Spirometry and bronchodilator response 
test were performed at the time of inclusion of 
patient in the protocol. The functional evalua-
did not met the same criteria and therefore were 
not granted the benefit (non-EMR).(4)
The criteria for being granted the benefit are 
as follows: presenting continuous, daily asthma 
symptoms; requiring the use of a short-acting 
bronchodilator at least twice per day; presenting 
a PEF or FEV1 < 60% of predicted, prior to 
bronchodilator use, on spirometry tests(10); and 
presenting nocturnal symptoms at least twice 
per week.
Patients diagnosed with COPD were excluded 
from the present study, as were patients with 
severe concomitant pulmonary disease and 
smokers or former smokers with a smoking 
history of more than five pack-years.
Study protocol
Demographic data (age, race, gender, weight 
and height) were obtained at the time of 
inclusion.
In relation to history of asthma, we evalu-
ated the age at onset of asthma symptoms, 
duration (date of diagnosis), trigger factors 
and asthma control. We also recorded the 
frequency and number of episodes of exacerba-
tion, which was defined as an increase of diurnal 
and nocturnal symptoms requiring the use of 
quick-relief bronchodilator, more than 8 times 
per day, consecutive nighttime awakenings or 
treatment with systemic corticosteroids given as 
pulse therapy.(12,13) We registered the number of 
emergency room visits in the preceding year and 
the lifetime/previous-year incidence of hospi-
Table 1 - Spirometry of the studied patients at the time of inclusion.
Parameter Total EMR Non-EMR p*
(n = 60) (n = 29) (n = 31)
Pre-BD
FVC, L 3.13 ± 0.88 2.89 ± 0.84 3.34 ± 0.87 0.04
FEV1, L 1.93 ± 0.66 1.59 ± 0.49 2.24 ± 0.66 NA
FEV1,% 62.18 ± 16.57 49.04 ± 9.25 74.5 ± 11.7 NA
FEV1/FVC 61.58 ± 10.90 56.01 ± 10.52 66.79 ± 8.50 NA
Post-BD
FVC, L 3.43 ± 0.88 3.30 ± 0.9 3.55 ± 0.85 0.33
FEV1, L 2.23 ± 0.72 1.96 ± 0.66 2.47 ± 0.70 NA
FEV1,% 71.50 ± 17.53 58.55 ± 13.54 83.42 ± 11.15 NA
FEV1/FVC 64.71 ± 11.08 59.82 ± 11.69 69.20 ± 8.45 NA
ΔFEV1 BD L 19.01 ± 18.47 24.4 ± 22.15 14.05 ± 12.83 0.06
EMR: group of patients accepted into the Exceptional Medication Request Program; non-EMR: group of patients not 
accepted into the Exceptional Medication Request Program; BD: bronchodilator; and NA: not applicable. *Unpaired 
t-test.
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the fact that that the prevalence of one annual 
pulse of oral corticosteroids per year is 60% in 
patients regularly monitored at the Hospital 
São Paulo Asthma Research Outpatient Clinic. 
If this event occurred in 75% of the group with 
mild asthma (the study group) and in 15% in 
the control group, we would need 29 patients in 
each group in order to observe this difference, 
with an α = 0.05 (two-tailed) and statistical 
power of the test of 80% (β = 0.2).(16)
The data were tabulated using Microsoft 
Excel 2000. The tool used to conduct the statis-
tical calculation was the Statistical Package for 
the Social Sciences, version 13.0 (SPSS Inc., 
Chicago, IL, USA).
Results
Sixty patients were included in the study. The 
group of patients who received free medication 
(EMR group) presented lower prebronchodilator 
FVC values, and this difference was statistically 
significant. The variable FEV1 was not statisti-
cally evaluated, since it was not related to any 
of the inclusion criteria. The two studied groups 
were homogeneous in relation to postbron-
chodilator ΔFEV1 (Table 1).
There no statistically significant difference 
between the groups in terms of age, body mass 
index, gender, race, time since diagnosis, history 
of smoking, rhinitis, gastroesophageal reflux, 
tion consisted of spirometry, with conventional 
bronchodilator response test. Spirometry was 
performed in accordance with the norms of the 
“Pulmonary Function Test Guidelines” issued in 
2002.(14)
When available, sputum cytology results were 
registered in order to evaluate airway inflam-
mation. These examinations were performed 
in the Unifesp Department of Pulmonology 
Laboratory for Airway Inflammation Research. 
The procedures for the collection and processing 
of the sputum were performed in accord-
ance with methods previously described.(15) The 
total number of cells was evaluated, as were 
the percentages of macrophages, neutrophils, 
lymphocytes and eosinophils.
Descriptive statistical methods were used in 
order to profile of the studied population. The 
chi-square test (together with the partition chi-
square test, when necessary) was used to compare 
the two groups in terms of the frequency of 
the categorical variables. The unpaired t-test 
was used to compare the two groups as for the 
continuous variables with normal distribution. 
The nonparametric Mann-Whitney test was 
used to compare the two groups in terms of the 
continuous variables with non-normal distribu-
tion. We adopted a value of 5% in order to reject 
the null hypothesis in all tests.
In order to calculate the ideal size of the 
sample to be obtained, we took into account 
Table 2 - Demographic characteristics, asthma history, comorbidities and control of patients at the time of 
inclusion.
Characteristic Total EMR Non-EMR p*
(n = 60) (n = 29) (n = 31)
Age,a years 41.88 ± 13.25 40.83 ± 13.16 42.87 ± 13.47 0.55
BMI,a kg/m2 26.75 ± 6.17 26.17 ± 7.08 27.28 ± 5.23 0.49
Female, % (n) 61.7 (37) 58.6 (17) 64.5 (20) 0.64
Caucasian, % (n) 67.8 (40) 79.3 (23) 54.8 (17) 0.14
Onset of asthma symptoms (> 12 years) 51.7 (31) 44.8 (13) 51.6 (16) 0.59
Rhinitis, % (n) 86.7 (52) 86.2 (25) 87.1 (27) 0.91
GERD, % (n) 15 (9) 13.8 (4) 16.1 (5) 0.80
SAH, % (n) 23.3 (14) 13.8 (4) 32.2 (10) 0.09
Obesity, % (n) 20 (12) 13.8 (4) 25.8 (8) 0.24
Former smoker, % (n) 10 (6) 13.8 (4) 6.5 (2) 0.34
Asthma control, % (n)
Uncontrolled 25 (15) 80 (12) 20 (3)
Partially controlled 65 (39) 44 (17) 56 (22) 0.002
Controlled 10 (6) 0 (0) 100 (6)
EMR: group of patients accepted into the Exceptional Medication Request Program; non-EMR: group of patients not 
accepted into the Exceptional Medication Request Program; BMI: body mass index; GERD: gastroesophageal reflux disease; 
and SAH: systemic arterial hypertension. aMean ± SD. *Chi-square test.
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The EMR group presented significantly 
greater numbers of lymphocytes and eosinophils 
in the induced sputum samples collected prior to 
the time of inclusion, in relation to the non-EMR 
group (Table 4 and Figure 1).
Discussion
The criteria for patient acceptance into 
the EMR program, outlined in Complementary 
Directive SAS/MS 12, issued on 12 November, 
2002,(4,10) were appropriate for the identification 
of the patients presenting the greatest disease 
severity. Those criteria stratified patients based 
on the frequency at which they used health care 
resources. The patients selected to receive medi-
cation from the EMR presented a higher number 
of emergency room visits in the preceding year, 
a higher number of exacerbations and a more 
frequent need for corticosteroid pulses. It is 
known that patients with severe asthma who 
achieve control of the disease visit the emer-
gency room less frequently and are less likely to 
receive oral corticosteroid pulses, although these 
severity markers present no significant associa-
tion with corticosteroid dependency.(17)
In the present study, we observed that the 
emergency room visits did not result in hospi-
talization or admission to the ICU; therefore, the 
attacks presented good response to the emer-
gency treatment, which characterizes mild to 
moderate bronchospasm attacks,(2) as well as 
characterizing patients likely to have received 
insufficient maintenance treatment. Therefore, 
the EMR directive criteria were efficacious in 
identifying patients with frequent exacerba-
tions and uncontrolled asthma, who are those 
that would potentially benefit most from the 
adequate and continuous use of medication.
arterial hypertension or obesity. Most patients in 
the EMR group presented uncontrolled asthma, 
whereas most patients in the non-EMR group 
presented controlled asthma, and this differ-
ence was statistically significant (Table 2 and 
Figure 1).
The EMR group presented a higher number 
of exacerbations in the preceding year, with a 
higher number of emergency room visits, as well 
as a higher percentage of patients who received 
at least one pulse of oral corticosteroids in the 
same period. These differences were statistically 
significant. As for the number of lifetime/previ-
ous-year hospitalizations and ICU admissions, no 
statistically significant differences were observed 



















Figure 1 - Asthma control, number of emergency room 
(ER) visits in the preceding year and corticosteroid 
(CO) pulses in the preceding year, together with the 
percentage of lymphocytes and eosinophils in the 
induced sputum of patients accepted or not accepted 
into the Exceptional Medication Request Program 
(EMR group and non-EMR group, respectively).
Table 3 - Clinical characteristics of asthma at the time of inclusion.
Characteristic Total EMR Non-EMR p
(n = 60) (n = 29) (n = 31)
Exacerbations in the preceding year,a n 1.13 ± 1.73 1.55 ± 2.08 0.74 ± 1.24 0.04*
Visits to the ER in the preceding year, % (n) 28.3 (17) 51.7 (15) 6.5 (2) < 0.001**
Hospitalizations throughout life, % (n) 48.3 (29) 51.7 (15) 45.2 (14) 0.61**
Hospitalizations in the preceding year, % (n) 10 (6) 17.2 (5) 3.2 (1) 0.07**
ICU admissions throughout life, % (n) 16.7 (10) 20.7 (6) 12.9 (4) 0.42**
OC pulse in the preceding year, % (n) 60 (36) 96.6 (28) 25.8 (8) < 0.001**
EMR: group of patients accepted into the Exceptional Medication Request Program; non-EMR: group of patients not 
accepted into the Exceptional Medication Request Program; R: emergency room; ICU: intensive care unit; and OC: oral 
corticosteroid. aMean ± SD. *Unpaired t-test, and **Chi-square test.
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treatment, as well as correlating with the use 
of inhaled corticosteroid.(27) The higher number 
of lymphocytes in the sputum of patients in the 
non-EMR group was not a significant difference 
and has no clinical relevance.
It is know that the minority populations 
(Blacks, Hispanics and low-income individuals) in 
developed countries use less anti-inflammatory 
medication and, consequently, more frequently 
evolve to uncontrolled asthma.(22) However, 
genetic studies have shown that Black patients 
present alterations that explain the greater 
disease severity.(28) In both groups, there was a 
predominance of female patients and Caucasian 
patients; the groups were homogenous in terms 
of age and presence of comorbidities (rhinitis, 
gastroesophageal reflux, systemic arterial hyper-
tension, obesity and smoking). Although no 
statistically significant differences for these vari-
ables were observed between the two groups, 
many of them have been associated with asthma 
severity.(9,29)
The variations observed in the functional 
study of our patients are related to the inclusion 
criteria applied for each group. Therefore, as 
expected, the patients who met the EMR accept-
ance criteria were the most functionally severe 
(Table 1). The FEV1/FVC ratio is considered the 
gold standard measurement for the identifica-
tion of airway obstruction, whereas FEV1 is used 
to grade this obstruction. The advantage of 
using FEV1 as an asthma severity marker is the 
objectivity and the reproducibility of this vari-
able.(14)
The control of asthma influences the value 
of the total cost by reducing expenses related 
to the use of health care resources.(3) Therefore, 
the distribution of asthma medication at no cost 
leads to a decrease in the number of exacer-
bations of the disease and, consequently, to a 
One limitation of the present study was the 
potential bias related to the registration of the 
use of the health care resources, although we 
were able to confirm the occurrence of emer-
gency room visits and exacerbations using the 
data contained in the emergency room medical 
charts.
Strategies have recently been developed to 
evaluate the complexity of the treatment and 
monitoring of asthma patients as well as to 
identify phenotypes, especially that of diffi-
cult-to-control severe asthma. Therefore, the 
underuse of preventive medication, especially of 
inhaled corticosteroids, as well as inappropriate 
management—which includes exposure to trigger 
factors, inefficacious use of medication adminis-
tered through inhalation and failure to identify 
the early signs of exacerbation—contribute to 
the collection of disparities in compliance with 
the consensus recommendations established for 
asthma patients.(18-20) Studies suggest that the 
lack of adherence to treatment due to costs or 
patient failure to appropriately prioritize treat-
ment can contribute to sub-optimal use of 
medication.(21-24)
A reduction in the proportion of eosi-
nophils in the induced sputum is to be expected 
in patients with controlled asthma.(25) In the 
present study, the inflammatory characteristics, 
evaluated by induced sputum cytology, differed 
between the two groups evaluated. Patients in 
the EMR group presented an increase in the 
number of eosinophils, which suggests a lack of 
disease control in this group. In the non-EMR 
group, the median number of eosinophils in the 
sputum was within the normal range, due to the 
greater proportion of controlled patients in this 
group (Tables 2 and 4).(24) Therefore, induced 
sputum cell counts can be used as a marker and 
add quality to the monitoring of the asthma 
Table 4 - Comparison of the median values of the total and differential count of the cells of the induced 
sputum of the patients who underwent sputum cytology prior to the time of inclusion.
Count Total EMR Non-EMR p*
(n = 60) (n = 29) (n = 31)
Total number of cells × 106 0.28 0.24 0.60 0.43
Macrophages, % 26.38 25.75 33.00 0.82
Neutrophils, % 56.87 50.00 60.50 0.92
Lymphocytes, % 4.87 6.00 2.25 0.03
Eosinophils, % 3.63 13.00 2.00 0.04
EMR: group of patients accepted into the Exceptional Medication Request Program; and non-EMR: group of patients not 
accepted into the Exceptional Medication Request Program. *Mann-Whitney test.
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to increasing emergency room costs.
The EMR acceptance criteria (presenting 
continuous, daily asthma symptoms; requiring 
the use of a short-acting bronchodilator at least 
twice per day; presenting a PEF or FEV1 < 60% 
of the predicted, prior to bronchodilator use, on 
spirometry tests; and experiencing nocturnal 
symptoms at least twice per week) allowed 
the identification of patients who had visited 
the emergency room more often, presented 
a higher number of exacerbations/oral corti-
costeroid pulses, as well as a greater degree 
of airway inflammation, as evidenced by the 
greater proportion of eosinophils in the induced 
sputum.
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